Company research
ANTARES PHARMA, INC.
CIK 1016169Updated Nov 16, 2026
Securities
Historical securities (1)
ATRS · NASDAQ · equity · closed May 24, 2022Name history
ANTARES PHARMA INC · through May 15, 2008ANTARES PHARMA INC · through Jan 10, 2006ANTARES PHARMA INC /MN/ · through May 14, 2002MEDI JECT CORP /MN/ · through Mar 14, 2001
ATRS price & chart
Historical security
This listing closed May 24, 2022. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2021 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 257,505,000Source | 212,531,000Source | 132,751,000Source | 88,277,000Source |
| Property, Plant and Equipment, NetUSD | 26,015,000Source | 24,020,000Source | 15,961,000Source | 14,895,000Source |
| GoodwillUSD | 1,095,000Source | 1,095,000Source | 1,095,000Source | 1,095,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 17,879,000Source | 7,693,000Source | 478,000Source | 831,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 65,913,000Source | 53,137,000Source | 23,201,000Source | 27,892,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 56,697,000Source | 42,221,000Source | 35,074,000Source | 18,976,000Source |
| Inventory, NetUSD | 11,544,000Source | 18,216,000Source | 16,000,000Source | 11,350,000Source |
| Assets, CurrentUSD | 174,272,000Source | 126,591,000Source | 108,446,000Source | 71,308,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,532,000Source | 4,877,000Source | 3,416,000Source | 2,648,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,774,000Source | 4,621,000Source | 5,463,000Source | — |
| Other Assets, NoncurrentUSD | 1,427,000Source | 1,529,000Source | 1,308,000Source | 148,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 81,747,000Source | 93,416,000Source | 78,251,000Source | 49,276,000Source |
| Stockholders’ equity: | ||||
| Retained Earnings (Accumulated Deficit)USD | -176,337,000Source | -222,626,000Source | -278,827,000Source | -276,800,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -685,000Source | -683,000Source | -702,000Source | -703,000Source |
| Stockholders' Equity Attributable to ParentUSD | 175,758,000Source | 119,115,000Source | 54,500,000Source | 39,001,000Source |
| Additional Paid in Capital, Common StockUSD | 351,079,000Source | 340,756,000Source | 332,377,000Source | 314,907,000Source |
| Liabilities and EquityUSD | 257,505,000Source | 212,531,000Source | 132,751,000Source | 88,277,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 58,930,000Source | 63,205,000Source | 32,415,000Source | 27,193,000Source |
| Operating Lease, Liability, CurrentUSD | 904,000Source | 1,203,000Source | 1,249,000Source | — |
| Accounts Payable, CurrentUSD | 17,056,000Source | 16,194,000Source | 12,905,000Source | 11,135,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,576,000Source | 4,816,000Source | 5,441,000Source | — |
| Other Liabilities, NoncurrentUSD | 0Source | 726,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 35,043,000Source | 25,635,000Source | 16,523,000Source | 11,997,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 65,913,000Source | 53,137,000Source | 45,721,000Source | — |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 1,500,000Source | 16,230,000Source | — | 3,043,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 18,241,000Source | 24,669,000Source | 40,395,000Source | 22,083,000Source |
| Short-term InvestmentsUSD | 1,245,000Source | — | 22,520,000Source | 0Source |
cash flow · annual statements
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 46,289,000Source | 56,201,000Source | -2,027,000Source | -6,515,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 3,901,000Source | 2,627,000Source | 2,557,000Source | 2,724,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,015,000Source | 7,948,000Source | 6,470,000Source | 4,927,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 14,476,000Source | 7,128,000Source | 16,095,000Source | 7,099,000Source |
| Increase (Decrease) in InventoriesUSD | -2,748,000Source | 2,728,000Source | 4,975,000Source | 2,667,000Source |
| Increase (Decrease) in Accounts PayableUSD | 2,189,000Source | 2,594,000Source | 926,000Source | 5,164,000Source |
| Deferred Income Tax Expense (Benefit)USD | 13,939,000Source | -46,982,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 36,619,000Source | 21,320,000Source | -10,615,000Source | -17,322,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -3,852,000Source | 8,167,000Source | -19,995,000Source | 11,606,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 6,617,000Source | 9,615,000Source | 2,350,000Source | 854,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 2,841,000Source | 1,367,000Source | 1,131,000Source | 543,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -19,990,000Source | 447,000Source | 25,919,000Source | 7,045,000Source |
| Repayments of Long-term DebtUSD | 40,000,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 12,776,000Source | 29,936,000Source | -4,691,000Source | 1,330,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,736,000Source | 3,538,000Source | 3,025,000Source | — |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | 322,000Source | 210,000Source |
| AmortizationUSD | — | — | 352,000Source | 599,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 8,015,000Source | — | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 65,913,000Source | 53,137,000Source | 45,721,000Source | — |
| DepreciationUSD | 2,864,000Source | 2,341,000Source | 2,205,000Source | 2,125,000Source |
| Gain (Loss) on Disposition of AssetsUSD | 38,591,000Source | -22,000Source | — | 12,500,000Source |
| GoodwillUSD | 1,095,000Source | 1,095,000Source | 1,095,000Source | 1,095,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 15,982,000Source | -46,280,000Source | — | — |
| Inventory Write-downUSD | 359,000Source | 356,000Source | 708,000Source | 255,000Source |
| Net Income (Loss) Attributable to ParentUSD | 46,289,000Source | 56,201,000Source | -2,027,000Source | -6,515,000Source |
| Nonoperating Income (Expense)USD | -3,662,000Source | -3,698,000Source | -3,019,000Source | -2,414,000Source |
| Other Nonoperating Income (Expense)USD | -51,000Source | 89,000Source | 530,000Source | 261,000Source |
| Payments to Acquire InvestmentsUSD | 1,245,000Source | — | 22,645,000Source | — |
| Proceeds from Issuance of Common StockUSD | 0Source | — | 7,781,000Source | 7,114,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 20,000,000Source | — | 15,000,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 5,182,000Source | 1,814,000Source | 4,405,000Source | 474,000Source |
income statement · annual statements
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Total RevenueUSD | 183,982,000Source | 149,599,000Source | 123,864,000Source | 63,554,000Source |
| Cost of RevenueUSD | — | — | 50,475,000Source | 31,065,000Source |
| Selling, General and Administrative ExpenseUSD | 73,857,000Source | 62,759,000Source | 61,773,000Source | 36,762,000Source |
| Operating Income (Loss)USD | 65,933,000Source | 13,619,000Source | 992,000Source | -4,101,000Source |
| Other Nonoperating Income (Expense)USD | -51,000Source | 89,000Source | 530,000Source | 261,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 62,271,000Source | 9,921,000Source | -2,027,000Source | -6,515,000Source |
| Income Tax Expense (Benefit)USD | 15,982,000Source | -46,280,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 46,289,000Source | 56,201,000Source | -2,027,000Source | -6,515,000Source |
| Earnings Per Share, BasicUSD per share | 0.27Source | 0.34Source | — | — |
| Earnings Per Share, DilutedUSD per share | 0.26Source | 0.33Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 169,226,000Source | 166,066,000Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 174,733,000Source | 170,155,000Source | — | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 156,640,000Source | 135,980,000Source | — | — |
| Current Income Tax Expense (Benefit)USD | 2,043,000Source | 702,000Source | — | — |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | — | — | 73,389,000Source | 32,489,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 62,626,000Source | 10,284,000Source | -1,734,000Source | -6,696,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | 0.27Source | 0.34Source | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | 0.26Source | 0.33Source | — | — |
| Interest ExpenseUSD | 3,611,000Source | 3,787,000Source | 3,549,000Source | 2,675,000Source |
| Nonoperating Income (Expense)USD | -3,662,000Source | -3,698,000Source | -3,019,000Source | -2,414,000Source |
| Research and Development ExpenseUSD | 14,502,000Source | 10,121,000Source | 10,624,000Source | 12,328,000Source |